

1 **R-phycoerythrin alginate/shellac beads by external gelation: process**
2 **optimization and the effects of gastrointestinal digestion for nutraceutical**
3 **applications**
4

5 **Pablo Castro-Varela^{1,2*}, Mónica Rubilar³, Antonio Martínez-Férez⁴, David**
6 **Fuentes-Ríos⁵, Juan Manuel López-Romero⁵, Claudio Alarcon⁶, Roberto Abdala-**
7 **Díaz¹, Félix L. Figueroa¹**

8 ¹Institute of Blue Biotechnology and Development (IBYDA), Grice-Hutchinson
9 Experimentation Centre, Department of Ecology, Faculty of Sciences, Universidad de
10 Málaga, Spain.

11 ²Department of Botany, Faculty of Natural and Oceanographic Sciences, Universidad de
12 Concepción, Chile.

13 ³Department of Chemical Engineering, Faculty of Engineering and Sciences, Universidad
14 de La Frontera, Chile.

15 ⁴Department of Chemical Engineering, Faculty of Sciences, Universidad de Granada, Spain.

16 ⁵Department of Organic Chemistry, Faculty of Sciences, Universidad de Málaga, 29017-
17 Málaga, Spain.

18 ⁶Department of Electronic Engineering, Faculty of Engineering and Sciences, Universidad
19 de La Frontera, Chile.

20
21 ***Corresponding author: pablo.castro@uma.es**

22 **Keywords:** alginate/shellac, ionic gelation, simulated gastrointestinal digestion,
23 antiproliferative activity

10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

28 **Abstract**

1
2
3 29 *Sarcopeltis skottsbergii* is an endemic polar red alga species of South America. Around
4 30 20,000 tons of dried algae from this macroalga are produced and sold primarily in Europe
5
6 31 and Asia. Modifying the process variables of technologies to protect R-phycoerythrin from
7 32 macroalgal biomass and the methodology followed are extremely important for
8
9 33 maintaining the biotechnology properties of the extracts. This study aimed to evaluate an
10 34 alginate/shellac mixture as wall material to develop an aqueous phycoerythrin (R-PE)
11 35 encapsulation system by external gelation and to determine the effect of encapsulation on
12 36 the properties of R-PE released during simulated gastrointestinal digestion. The Taguchi
13 37 method was implemented to formulate beads with a high R-PE encapsulation efficiency
14 38 (EE). The effect of the variables: feeding flow (90 and 20 mL h⁻¹), distance (5 and 10cms),
15 39 and CaCl₂ (5 and 15 g L⁻¹) were optimized, and the bead size, sphericity factor (SF), and
16 40 total R-PE content were characterized. Finally, the optimal alginate/shellac beads were
17 41 subjected to *in vitro* dynamic gastrointestinal digestion. The results show that the beads
18 42 formed under optimal conditions reached an EE value of 97.5%. The CaCl₂ concentration
19 43 and feeding flow most affected the R-PE EE. The release of R-PE from alginate/shellac was
20 44 affected at acid pH 1; however, the concentration was under 10% of the total R-PE
21 45 content. A second-order model was tested to describe the release of phycoerythrin from
22 46 the beads at 1, 3, and 5 pH values. The results showed that the release follows two stages,
23 47 wall release (stage 1) and core release (stage 2), showing promising targeting properties
24 48 in terms of time and pH. The R-PE extract and encapsulated R-PE were partially degraded
25 49 in gastric and intestinal conditions; the mouth did not detect signals from the protein
26 50 profile. The encapsulation of alginate/shellac led to higher R-PE contents at the end of
27 51 digestion than non-encapsulated R-PE, suggesting a protective role. Significantly, from
28 52 permeate streams, equivalent to the absorption of encapsulated R-PE, the bioavailability
29 53 was 2.5 times higher than non-encapsulated R-PE. NMR results indicate the presence of
30 54 R-PE and its methyl amino acids and oligosaccharides between 0.5-2.5 and 3.8-6.8 ppm,
31 55 respectively. A high selectivity index (> 10) was observed for the R-PE extract on the HCT-
32 56 116 human colon cancer cell line. The alginate/shellac as a wall material and ionic gelation
33 57 technology used may determine the release of the R-PE pigment at an intestinal site and
34 58 its antiproliferative effect on health.

51
52 59

53
54 60

55
56
57 61

58
59
60 62

61
62
63
64
65

63 1. Introduction

64 The ability to create a biocompatible wall material that allows for high loading of bioactive
65 agents with no premature release of the payload before reaching the target is crucial to
66 the success of various nano/micro-encapsulation procedures [1,2]. Biocompatibility of the
67 wall matrix, high loading of desired bioactive components, and providing a controlled
68 release mechanism are some factors to consider in the selection of such matrices to serve
69 as an efficacious delivery vehicle [3].

70 As one of the important classes of food-based encapsulation systems, biopolymeric
71 nano/microparticles can be constructed via a single biopolymer matrix (through the
72 precipitation process of carbohydrates or protein desolvation mechanism) [4]; nanogels of
73 particular biopolymers (e.g., alginate, whey/soy protein, chitosan, etc.) [5,6]; nano-
74 tubes/fibrils of whey proteins [7], or a complexation mechanism of two oppositely charged
75 biopolymers (commonly a protein and a polysaccharide) [8].

76 Polysaccharide-based capsules are important in encapsulation [9]. Their main functions
77 are the successful encapsulation, transportation, and controlled release of the capsule
78 content to the external environment [10]. For example, alginate is a natural anionic
79 polysaccharide widely used to prepare capsule or pearl encapsulation systems due to its
80 appealing physicochemical properties, biocompatibility, widespread availability, and low
81 cost [11]. The functionality of alginate beads largely depends on their permeability and
82 physicochemical stability. This alginate capsule has a retention and selective release,
83 making it a suitable carrier for biotechnology applications; however, its relatively high
84 porosity is inadequate for some industrial applications [12]. To overcome this problem,
85 blends of alginate and other polymers, such as shellac, may be used to reduce wall porosity
86 [13,14]. Shellac is a natural polymer from the insect *Kerria lacca* and is considered a food
87 additive by the FDA (The United States Food and Drug Administration). In addition, it has
88 a protective effect on gastric fluid, which is an advantage when used in microcapsules to
89 improve probiotic resistance [15]. Thanks to its excellent film forming and protective
90 properties, nontoxicity, and biodegradability, this natural polymer is widely used in
91 adhesives, thermoplastics, sealants, insulating materials, and coating materials in the food
92 and pharmaceutical industries [16] and also used as an oleogelator [17]

93 In recent years, the shellac biopolymer has attracted significant interest in the
94 development of different encapsulation systems. Experiences have validated its
95 incorporation as an additional external layer to coat capsules [17,18]. The combination of
96 alginate and shellac has been used to protect the aqueous extract of riboflavin by internal

97 and external gelation [18], microorganisms like probiotics [19] and lipophilic (sunflower
98 oil) compounds to develop an oil encapsulation system by external gelation [20].

99 Since the extracted algal proteins are intended for human consumption, it is crucial to
100 determine their digestibility under human gastric and intestinal conditions. High
101 digestibility would enable greater absorption of the protein, or its amino acids or short
102 peptides. Given that human digestive proteases have their specificity to bonds near certain
103 amino acids, it is important to verify that human proteases can digest algal protein. Protein
104 digestibility may be assessed by simulating gastrointestinal conditions with standard
105 protocols [21]. Moreover, it is important to highlight that the biological activity of algae
106 proteins may decrease or be modified by the digestive enzymes during their passage
107 through the gastrointestinal tract before crossing the intestinal barrier into the blood
108 circulation system [22]. Additionally, it is crucial to carry out *in vitro* and *in vivo*
109 bioavailability and bioaccessibility studies, as more scientific evidence is needed to support
110 the benefits of algae compounds described to date to validate their efficacy, especially *in*
111 *vivo* [23].

112 The phycoerythrin (R-PE) is an oligomeric protein of 240 kDa with three subunits α (about
113 16 kDa), β (about 21 kDa), and γ (about 39 kDa), and they are bound to specific cysteines
114 by thioether bonds [24]. The study of phycobiliproteins focuses chiefly on therapeutic
115 (bioactive) applications, i.e., the anti-inflammatory, antiviral, hepatoprotective, and
116 anticarcinogenic capacities of R-PE [25–27]. In previous studies in our group, we optimized
117 extraction of R-phycoerythrin pigment from the red alga *Sarcopeltis skottsberggi* by high-
118 pressure homogenization (HPH-assisted extraction). The concentrated extract is
119 characterized by high yield, satisfactory purity, and antioxidant activities.

120 Considering the potential of the alginate/shellac model system to protect hydrophilic and
121 lipophilic compounds and the advantages of the extrusion and co-extrusion process, this
122 study aimed to develop alginate/shellac beads by external gelation as a model system to
123 encapsulate R-phycoerythrin efficiently, and to evaluate the effect of *in vitro* simulated
124 gastrointestinal digestion and cytotoxic effects on different human tumor lines on R-
125 phycoerythrin beads. The optimal process conditions to prepare beads with efficiency
126 encapsulation (EE) were determined by the Taguchi method with an orthogonal array
127 $L_4(2^3)$. The effect of the variables flow rate, distance, and concentration of calcium chloride
128 (CaCl_2) solution on the EE was evaluated. The particle size, release properties, confocal
129 laser microscopy (CLSM), and scanning electron microscopy (SEM) were investigated. The
130 best results obtained under optimal conditions were selected and the parameters of
131 bioaccessibility and bioavailability processes on the simulation gastrointestinal system
132 (SIMUGIT), SDS-PAGE, NMR, and cytotoxic effects on various human tumor lines such as

133 human colon cancer (HCT-116), human melanoma (G-361), human leukemia (U-937) and
134 in the human gingival fibroblasts cell line (1065SK) were assessed.

135

136 **2. Materials and methods**

137 **2.1 Materials**

138 Alginate and calcium chloride were purchased from Sigma Aldrich (St. Louis, MO). The
139 aqueous shellac solution NORELAC B20 was obtained from Norevo (Germany). NORELAC
140 B20 is a 25% solid ammoniated aqueous shellac solution based on a selected shellac of
141 high and uniform quality refined by solvent extraction. The bioactive, R-phycoerythrin
142 (biliprotein pigment), was obtained from the red alga *Sarcopeltis skottsbergii* after
143 optimization of extraction processes [28].

144 **2.2 Formulation of wall material (WM)**

145 Using a magnetic stirrer, a sodium alginate solution (20 g/L) was prepared by mixing the
146 alginate powder with distilled water under agitation at 700 rpm. The suspension was
147 maintained under gentle agitation (1 h) until complete hydration and left to stand for 60
148 min for deaeration. The WM was prepared by mixing an alginate solution (20 g/L) and
149 shellac solution (250 g/L), according to Ben Messaoud et al. (2016) with some
150 modifications. Then, the pH of the resulting solution was adjusted to pH 7.5 with 1 M NaOH
151 solution.

152 **2.3 Formulation of beads by external gelation.**

153 Fig. 1 illustrates the process of preparing the alginate/shellac bead system with the
154 bioactive (B). The B/WM ratios (80/20 to 20/80 %v/v) were prepared by mixing the
155 bioactive (R-PE) with the previously prepared WM using continuous agitation (200 rpm for
156 15 min). The B/WM ratios were extruded by a controlled flow system pump (SyringePump,
157 Inc.) through a 0.3mm nozzle and dripped into 100mL of a gelling bath containing CaCl₂
158 (5-15 g/L) to produce the beads.

159 The gelling bath was prepared by dissolving the CaCl₂ in an ethanol/water mixture (1:1
160 v/v). The flow rate (30-90 ml/h) and the distance (5-15 cm) from the tips of the syringe
161 to the surface of the gelling bath were evaluated. The beads formed were allowed to stand
162 in the gelling bath for 30 min to ensure crosslinking.

163

164

2.4 Experimental design for aqueous encapsulation

An experimental Taguchi design optimized R-PE encapsulation with high EE (%). A matrix L4(2³) with three independent variables and two levels of work (L1 and L2) was used, applying the criterion 'bigger is better': fed flow solutions of bioactive (R-PE)/WM (flow; L1:20 mL/h; L2:90mL/h), distance to the surface of the gelling bath (distance; L1:5cms; L2:15cms), and concentration of calcium chloride solution (CaCl₂; L1:5 and L2:15 g/L). The optimized theoretical equation (OTE) was determined by considering the average of the response with the greatest impact and identifying the most important variables and levels of work.

$$OTE = T + [(V_1, L_1) - T] + [(V_2, L_2) - T] + [(V_3, L_2) - T] \quad (Eq. 1)$$

where V is the variable, T is the average of the experimental run responses, and L is the working levels.

2.5 Determination of encapsulation efficiency (EE) of R-PE load.

The phycoerythrin concentration (R-PE) was determined spectrophotometrically using the Bennett and Bogorad equations [29] as follows:

$$Phycocyanin (R - PC) = Abs620 - \left[0.7 * \left(\frac{Abs650}{7.38} \right) \right] \quad (Eq. 2)$$

$$Allophycocyanin (A - PC) = Abs650 - \left[0.19 * \left(\frac{Abs620}{5.65} \right) \right] \quad (Eq. 3)$$

$$Phycoerythrin (R - PE) = Abs565 - [2.8 * R - PC] - (1.34) * (A - PC/12.7) \quad (Eq. 4)$$

The encapsulation efficiency of the microcapsule was calculated following the method of Ge et al. [30] with some modifications, by measuring the concentration of non-coated phycoerythrin and the concentration of phycocyanin added at the beginning of the microencapsulation process as follows:

$$EE(\%) = \frac{\text{initial concentration of Phycoerythrin} - \text{concentration of uncoated Phycoerythrin}}{\text{initial concentration of Phycoerythrin}} \times 100$$

188

189

190

191 **2.6 Sphericity factor (SF) of the beads.**

1
2
3 192 The size and shape of the beads were determined using the ImageJ software (National
4 193 Institutes of Health, USA). A digital camera coupled to a binocular microscope was used
5
6 194 to capture the images of the beads. SF was used to indicate the roundness of the beads,
7
8 195 as described by [31], where a value equal to zero indicates a perfect sphere and higher
9 196 values indicate a greater degree of shape distortion. SF was calculated according to Eq. 5:

$$11 \quad SF = \frac{D_{max} - D_{per}}{D_{max} + D_{per}} \quad (Eq. 5)$$

12
13
14
15 198 where D_{max} is the maximum diameter passing through the bead centroid (mm), and D_{per}
16 199 is the perpendicular diameter to D_{max} passing through the bead centroid (mm). All
17 199 samples were assayed in triplicate to determine the mean and standard error. The bead
18 200 size and shape were determined based on the measurement of 50 beads per sample.
19 201

202 **2.8 Mathematical Model of phycoerythrin release**

203 A mathematical model was proposed to describe the results of phycoerythrin release tests.
204 The model proposed was a second-order differential equation which is presented as
205 follows:

$$207 \quad y''(t) + y'(t)k_1 + y(t)k_2 + x'(t)k_3 + x(t)k_4 + x'(t - t_d)k_5 + x(t - t_d)k_6 = 0 \quad (Eq. 6)$$

208
209 In (Eq. 1), $x(t)$ describes the time at which pigment is released from the beads into the
210 aqueous solution since the start at time $t=0$ up to the end of the experiment. In contrast,
211 $y(t)$ represents the amount of phycoerythrin released measured in percentage units. The
212 starting conditions for $x(t)$, $y(t)$ and their derivative terms were all zero. The Laplace
213 transform was used for obtaining a transfer function (Eq. 2) between the input signal $x(t)$
214 and the output signal $y(t)$ using (Eq. 1), with s representing the complex frequency.

$$215 \quad \frac{Y(s)}{X(s)} = \frac{a_1}{(s+c_1)} + \frac{a_2 e^{-st_d}}{(s+c_2)} \quad (Eq. 7)$$

216 Where:

$$217 \quad k_1 = c_1 + c_2 \quad (Eq. 8)$$

$$218 \quad k_2 = c_1 \cdot c_2 \quad (Eq. 9)$$

$$219 \quad k_3 = a_1 \quad (Eq. 10)$$

$$220 \quad k_4 = a_1 \cdot c_2 \quad (Eq. 11)$$

$$221 \quad k_5 = a_2 \quad (Eq. 12)$$

$$222 \quad k_6 = a_2 \cdot c_1 \quad (Eq. 13)$$

223 The second-order transfer function shows a two-step first-order response, with the first
224 occurring at $t=0$ and the second at t_d . A series of parameters of the release response can

225 be calculated from the equation, such as the maximum release (M.R) of the first (S1) and
226 second (S2) stage, the time to reach the maximum value or stabilization time (S.T.), and
227 the time delay (t_d) between each phase, calculated as follows:

228 $M.R.S1 = a_1/c_1$ (Eq. 14)

229 $M.R.S2 = a_1/c_1 + a_2/c_2$ (Eq. 15)

230 $S.T.S1 = 5/c_1$ (Eq. 16)

231 $S.T.S2 = 5/c_2$ (Eq. 17)

232 Time delay = t_d (Eq. 18)

233

234 The parameters a_1 , a_2 , c_1 , c_2 , and t_d were adjusted to data showing phycoerythrin release
235 at three different pH values: 1, 3, and 5. The parameter adjustment was performed using
236 an evolutive algorithm. The evolutive algorithm considered five parameters, with the
237 minimization of the normalized root mean square error between data and model as the
238 evaluation function, following the algorithm presented by others [32].

239

240 **2.9 Gastrointestinal-Tract-Simulating Membrane Bioreactor (GITSMB)—SimuGIT**

241 The dynamic gastrointestinal simulator system used (SimuGIT) was developed by the
242 TEP025 Research Group in the Department of Chemical Engineering at the University of
243 Granada [33]. The dynamic *in vitro* Gastrointestinal-Tract-Simulating Membrane
244 Bioreactor GITSMB (SimuGIT), consists of a continuous stirred-tank reactor (CSTR)
245 connected in series to a continuous plug-flow tubular reactor (PFTR) equipped with a
246 monochannel tubular ceramic microfiltration membrane. The CSTR used to simulate
247 gastric digestion in the stomach is a benchtop fermenter supplied by Braun Biotech
248 International (Biostat B). It comprises a conventional autoclavable stirred tank glass vessel
249 equipped with an impeller stirrer (Rushton 180 W) and a proportional-integral-derivative
250 (PID) unit control system for the temperature, level, foam, dissolved oxygen, and pH. The
251 control system unit includes an RS-422 interface that enables the control of the CSTR with
252 a computer. The CSTR has an external jacket to maintain a constant temperature, such
253 that the temperature in the vessel is measured using a Pt-100 digital sensor and is
254 accurately controlled ($T_{setpoint} \pm 0.1$ °C) by the PID loop connected to a thermostatic
255 laboratory bath. The CSTR system also has sampling and reagent addition inlets using
256 several peristaltic pumps (Eyela, MP-3). The pH inside the CSTR is measured by a pH
257 electrode (Hamilton, Easyferm Plus K8) immersed in the vessel and adjusted by a pH
258 control system made by the authors based on data acquisition modules, which acts on two
259 different peristaltic pumps that dose the acid and basic solutions (HCl or NaHCO₃). The
260 digested solution exiting the CSTR is continuously driven to the PFR. To this end, the PID
261 control system acts on impulsion and return peristaltic pumps (two of the four peristaltic

262 pumps integrated into the benchtop fermented, as previously described), such that by
1 263 varying the flow rates of these pumps, the pressure inside the hydraulic circuits and the
2
3 264 product filtration rate can be regulated. In addition to this self-developed control pressure
4
5 265 mechanism, the operating pressure can be adjusted accurately (P setpoint ± 10 mmHg)
6
7 266 with a spring-loaded pressure-regulating valve (SS-R4512MM-SP, Swagelok) and
8
9 267 monitored by a digital pressure gauge (Endress + Hauser, Ceraphant PTC31). The
10
11 268 continuous PFR connected in series to the CSTR serves for the simulation of the conditions
12
13 269 in the intestine. It consists of a stainless-steel cylindrical tube (provided by Prozesstechnik
14
15 270 GmbH, Basel, Switzerland) equipped with a monochannel ceramic microfiltration (MF)
16
17 271 membrane in a tubular configuration provided by Atech Innovations GmbH. The MF
18
19 272 membrane used for the experiments is an inorganic one of α - Al_2O_3 active surface with a
20
21 273 mean pore diameter equal to $0.2 \mu\text{m}$ and molecular weight cut-off of 1.2 kDa (model 20N).
22
23 274 The dimensions of the selected membrane are 1000 mm in length, 6 mm in duct diameter,
24
25 275 and $2 \pm 0.5 \text{ mm}$ in thickness. This type of MF membrane also ensures a series of
26
27 276 advantageous characteristics, such as high resistance to temperature (suitable for steam
28
29 277 sterilization at 121°C) and pressure (up to 10 bar) during the cleaning protocols, pH
30
31 278 stability (0 to 14), possibility of back pulsing, very high abrasion resistance (against
32
33 279 aggressive chemical reagents), optimal permeability recovery, high selectivity and
34
35 280 performance, and long lifetime service. The PFR is integrated with the CSTR using a drive
36
37 281 and return system made of chemically resistant polyethylene tubes. Finally, a precision
38
39 282 electronic mass balance with USB connectivity (Sartorius, Quintix 5102, accuracy equal to
40
41 283 1 mg) is coupled to an automatic sampling and data registration system to register
42
43 284 permeate values (the bioaccessible fraction that crossed the membrane) over time.

285 **2.9.1 GITSMB Conditions**

- 40 286 • Gastric Phase

43 287 When the trial began, the bath temperature that kept the reactor jacket warm was set at
44
45 288 $37.5 \pm 1^\circ\text{C}$ throughout the process, and the reactor stirring speed was set at 50 rpm to
46
47 289 simulate the peristaltic movements of the stomach. Next, 800 mL of GSF and 14 mL of
48
49 290 SSF were prepared using the reagents mentioned in Section 6.5. The concentrations of
50
51 291 each reagent for each fluid were pre-established according to Brodkorb et al. [34]. Once
52
53 292 prepared, the GSF was introduced into the reactor and heated to 37.5°C . The pH dropped
54
55 293 to 3 at this point, as the empty stomach was simulated before adding the food with the
56
57 294 microcapsules. At the same time, 20 g of mineral water were weighed, and 1 g of
58
59 295 phycoerythrin was added. Two separate tests were carried out as two different samples
60
61 296 (encapsulated and nonencapsulated phycoerythrin) were chosen. The SSF was then mixed
62
63 297 with the food preparation + microcapsules; 1 mL alpha-amylase solution (75 U/mL), 0.1

298 mL $\text{CaCl}_2 \cdot 2\text{H}_2\text{O}$ of concentration 0.3 M, and 4.9 mL distilled water were added (final
299 salivary fluid to food preparation ratio of 1:1). The mixture was shaken for 2 min, and the
300 pH was adjusted to 7 (if necessary). Once the GSF was hot, the mixture of the food with
301 the SSF was added to the reactor tank, stirred for a few seconds, and an initial sample
302 was taken. Then, a 10 mL solution of pepsin (2000 U) and 50 mg of phospholipid (Lipoid
303 p45) were added, and the pH was adjusted to 3 by controlled dosing of 6 M HCl. From
304 then on, a sample was taken every 5 min for the next 30 min.

- Duodenum Phase

306 When the gastric phase ended with the last sample taken, the pH of the GSF was raised
307 to 6.5 by dosing 1 M NaHCO_3 at a rate of 2.05 mL/min, and a sample was taken after
308 adjustment. This pH simulates the action of pancreatic juices on the food being digested.
309 Intestinal enzymes were added: 10 mL solution of pancreatic lipase (2000 U/mL), biliary
310 salts (for a final concentration of 5 mM), 10 mL solution of pancreatin (10%), and 1 mL
311 solution of trypsin (50 mg/assay). Digestion in the duodenum takes about 10 min after
312 adding enzymes, and a sample was taken after that digestion period. The approximate
313 total duration of this phase (including pH rise, addition of enzymes, and digestion) was 30
314 min.

- Intestinal Absorption Phase

316 To simulate intestinal absorption, fluids from the bioreactor were pumped to flow through
317 the modular filtration system. A 0.2 μm membrane size was chosen for these trials based
318 on previous tests [35,36]. The system overpressure limit was set at 50 mmHg, so that the
319 diffusion of phycoerythrin through the membrane was due solely to passive transport. It
320 is important to remember that the ionization characteristics of a compound can profoundly
321 affect the rate of its transfer by passive diffusion because only the unionized species are
322 capable of passive diffusion across the membrane. Once the circuit was primed and fluids
323 began to fall into the bioreactor, the intestinal absorption phase was considered to have
324 begun and lasted 180min. Samples were taken at 30, 60, 90, 120, 150, and 180 min. Two
325 samples were taken each time, one from the fluid filtrated through the membrane
326 (permeate) and another from the retained fluid, which forms part of the colonic residue
327 (retained).

328 In summary, each simulation test lasted approximately 4 h: Gastric phase (30 min),
329 duodenal phase (30 min), and intestinal absorption phase (180 min). Each trial was
330 conducted in duplicate. Throughout the trial, the system program generated a data file
331 recording all the events and processes during the simulation. This file was then processed
332 in the computer to obtain information on all the variables.

333 **2.9.2 Analysis of the Samples**

334 All samples collected during the assay were refrigerated. Subsequently, the concentration
335 of phycoerythrin present in the fluids in each sample was measured using
336 spectrophotometry analysis according to Bennett & Bogorad, [29], polyacrylamide gel
337 electrophoresis (SDS-Page) and nuclear magnetic resonance (NMR). The concepts of
338 release or bioaccessibility and bioavailability were used to measure the amount of
339 phycoerythrin released along the digestive tube in the chymus and the amount absorbed
340 by the membrane, respectively. The release corresponds to the pigment fraction delivered
341 by microcapsules to the gastrointestinal tract during the gastric and duodenal phases and
342 was calculated using Equation (6), adapted from Rivas-Montoya et al. [33]. When release
343 and precipitation processes took place simultaneously, the same equation was used to
344 calculate the bioaccessible percentage as the released and non-precipitated fraction in the
345 chymus. On the other hand, bioavailability corresponds to the pigment fraction absorbed
346 by diffusion through the membrane during the intestinal absorption phase and was
347 calculated using Equation (7), adapted from Ariza et al. [37].

$$348 \quad \text{Bioaccessibility (\%)} = \frac{\text{pigment phycoerythrin in chymus}}{\text{initial pigment phycoerythrin in microcapsules}} \times 100 \quad (\text{Eq. 19})$$

$$349 \quad \text{Bioavailability (\%)} = \frac{\text{phycoerythrin amount in IAS}}{\text{initial pigment phycoerythrin in microcapsules}} \times 100 \quad (\text{Eq. 20})$$

350 where IAS means intestinal absorption samples. In both equations, the amounts of
351 phycoerythrin in the chymus and the microcapsules are expressed in milligrams of R-PE
352 by total biomass (mg g^{-1}).

353 **2.9.3 SDS polyacrylamide gel electrophoresis (SDS-PAGE):**

354 The hydrolysates of the encapsulated and non-encapsulated phycoerythrin were prepared
355 for SDS-PAGE using the protocol developed by [38], which combines TCA/acetone and
356 methanol washes and a phenol step for protein extraction. SDS-PAGE will be performed
357 according to Laemmli's procedure [39].

358 **2.9.4 Nuclear magnetic resonance (NMR)**

359 A 400 MHz Plus Avance II NMR spectrometer (Bruker, Switzerland) was used for nuclear
360 magnetic resonance analyses. ^1H NMR spectra were recorded at 400 MHz at room
361 temperature ($21\text{ }^\circ\text{C}$). Samples (15-30 mg) were dissolved in deuterated dimethyl sulfoxide
362 (DMSO-d_6 , 0.75 mL), with residual solvent peaks at $\delta = 2.50$ (DMSO) and $\delta = 3.42$ (H_2O)
363 ppm for ^1H . In some samples, D_2O (3 drops) was added.

364 **3.0 Cell Cultures**

1
2
3 365 To perform the cytotoxicity analysis, the five following cell lines were chosen: human
4 366 fibroblasts (1064sk, CIC-UGA, ES), human leukemia cell line (U-937, ATCC, USA), human
5 367 malignant melanoma (G-361, ATCC, USA), and colon cancer cell line (HCT-116, ATCC,
6 368 USA) stored in liquid nitrogen in the cell culture unit of the Central services for research
7 369 support (SCAI) of Malaga University (UMA). To maintain the cells, 1064sk, G-361, and
8 370 HCT-116s were previously cultured using Dulbecco's modified Eagle's medium (DMEM)
9 371 (Capricorn Scientific, ref. DMEM-HPSTA) supplemented with 10% fetal bovine serum
10 372 (Biowest, ref. S1810-500), 1% penicillin-streptomycin solution 100× (Capricorn Scientific,
11 373 ref. PS-B), and 0.5% of amphotericin B (Biowest ref. L0009-100). U-937 were grown in
12 374 RPMI-1640 medium (BioWhittaker, ref. BE12-167F) supplemented with 10% fetal bovine
13 375 serum (Biowest ref. S1810-500), 1% penicillin-streptomycin solution 100×, and 0.5% of
14 376 amphotericin B. The cells in suspension (U-937) were harvested upon reaching 70–75%
15 377 confluence and centrifuged at 1500 rpm for 5 min at room temperature. Once centrifuged,
16 378 the corresponding test or the subculture of the cells was carried out. The cells were kept
17 379 under subconfluence in an atmosphere-controlled incubator with 5% CO₂ at 37 °C.
18
19
20
21
22
23
24
25
26
27
28
29

30
31
32

30 **3.1 Analytic Method (MTT assay)**

33 382 For the cancer and healthy cell viability assay, U-937, HTC-116, G-361, and 1064sk cells
34 383 were incubated at encapsulated R-PE concentrations of 5 to 4.76×10^{-6} mg mL⁻¹ in serial
35 384 dilutions (1:1) from the alga *S. skottsbergii*. The experiment was conducted individually
36 385 with each cell line in a 96-well microplate for 72 h (37 °C, 5% CO₂ in a humid atmosphere).
37 386 The proliferation of these cell lines was estimated by the MTT (3-(4,5-dimethylthiazol- 2-
38 387 yl)-2,5-diphenyltetrazolium bromide) assay [40]. Briefly, 10 µL of the MTT solution (5 mg
39 388 mL⁻¹ in phosphate-buffered saline) was added to each well. The plates were incubated at
40 389 37 °C for 4 h. The yellow tetrazolium salt of MTT was reduced by mitochondrial
41 390 dehydrogenases of metabolically active viable cells to form insoluble purple formazan
42 391 crystals. Formazan was dissolved by adding acid-isopropanol (150 µL of 0.04 N HCl-2
43 392 propanol) and measured spectrophotometrically at 550 nm (Micro Plate Reader 2001,
44 393 Whittaker Bioproducts, USA). The relative cell viability was expressed as the mean
45 394 percentage of viable cells compared to the untreated cells. Four samples for each tested
46 395 concentration were included in each experiment. Measurements were taken in independent
47 396 experiments in triplicate.
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

397

398 **3.3 Calculation of the selectivity index (SI)**

399 The selectivity index determines the cytotoxic selectivity of the compounds tested and is
400 calculated by the ratio between the IC₅₀ as indicated in the following formula:

401
$$SI = (IC_{50} \text{ OF health cell}) / (IC_{50} \text{ of cancer cell})$$

402 [41] state that a selective compound presents a SI over 3.

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

428

1 429

2

3 430 **4.0 Results**

4

5

6 431 **4.1 Optimization of the encapsulation process**

7

8 432 The different combinations of alginate and shellac were tested for the liquid-core matrix.

9 433 Only the formulation alginate/shellac (75/25 %V/V) was satisfactory in determining the

10 434 basic process conditions of bead preparation. Thus, the effect of the process variables

11 435 (flow rate, distance, and concentration of CaCl₂) on the EE of R-PE was investigated (Figure

12 436 1). For this, 80 % of alginate/shellac mixture (wall material) was mixed with 20 % of R-

13 437 PE extract, and then extruded and dripped into CaCl₂ solution for 30min of gelation to form

14 438 beads. The R-PE encapsulation process was optimized where included the effect of three

15 439 independent variables, flow rate (90 and 20 ml min⁻¹), distance (10 and 5 cm), and CaCl₂

16 440 (5 and 15 g L⁻¹) on %EE were evaluated. Table 1 shows the results of EE (%), particle

17 441 size, and SF obtained under different conditions. The EE values ranged between 89 and

18 442 97%. From the Taguchi design, a higher CaCl₂ concentration, lower flow rate, and high

19 443 distance resulted in a high EE.

20

21 444 Figure 1 shows the effect of the working levels of each variable on the encapsulation

22 445 efficiency (degree of incline of the slope as a response to EE). The greater the difference

23 446 between levels 1 and 2 for a variable, the higher the change magnitude of the response.

24 447 The variable CaCl₂ showed a greater influence on the EE with an average difference of 7.0

25 448 units between the responses of working-level 1 (L1:5 g L⁻¹) and working-level 2 (L2:15 g

26 449 L⁻¹), followed by the variable distance, showed an influence on the EE with a difference of

27 450 1.50 units between the levels. The variable flow rate with a difference of 0.5 units between

28 451 the two working levels. Therefore, the variable CaCl₂ presented the highest difference

29 452 between flow rate and distance. Thus, the R-PE pigment can be more efficiently

30 453 encapsulated in beads coated with a low CaCl₂ (<15 g L⁻¹) due to the formation of an

31 454 encapsulating matrix where coating the capsules by Ca²⁺ reticulation of shellac leads to

32 455 the formation of a uniform and smooth layer at the surface of alginate capsules compared

33 456 to capsules prepared at 15 g L⁻¹ of CaCl₂, generating the formation of a non-uniform

34 457 external layer.

35

36 458 The coefficients of determination (R²) for the independent variables flow, distance, and

37 459 CaCl₂ were 2.5, 4.2, and 90.7%, respectively. The coefficient of determination for these

38 460 three variables was significant (p < 0.05) with R² = 97.4% indicating a good affinity or

39 461 association of the independent variables with the EE. The optimized theoretical equation

40 462 (OTE) for EE was determined using Eq (1), where T is equal to 97 %, which is the total

41

42

43

44

45

46

47

463 average of the response of experimental runs, and L is the working levels of the equation.
1 464 The OTE contributed to 97 % of the response, coinciding closely with the optimal
2 experimental value (Point N°1: 97.5 %). These results confirmed that combining the
3 465 control variables and working levels was sufficient to determine an optimum.
4
5
6

7 467 **4.2 Sphericity factor (SF) and scanning electronic microscopy of the beads**

8
9

10 468 The fluorescence observation and scanning electronic microscopy of the aqueous-core
11 469 alginate/shellac capsules are shown in Figures 2 and 3, respectively. Figure 3 shows SEM
12 images of optimal alginate/shellac beads from design point 1, which reached the highest
13 470 EE. The image shows that the bead surfaces are smooth and free of pores, which is
14 important for the stability of the beads because the pores facilitate the exit or loss of the
15 471 R-PE. However, the beads from design point 2 and 3 shows non-uniform particles and
16 472 rough surfaces. Figure 2 shows the R-PE distribution in the beads observed by CLSM. The
17 R-PE pigment was identified by the fluorescence of the chromophores group after the
18 473 external gelation process. A high-intensity fluorescence was emitted, homogeneously
19 474 distributed throughout the polymeric matrix in all design points. According to the design
20 points, the bead size was 10-50 mm. Additionally, the lowest SF value was found in design
21 475 point 1, reaching 0.04, whereas design point 3 showed the highest SF value at 0.358.
22 According to Chang et al. (2011), beads with an SF value lower than 0.05 are considered
23 476 spherical beads. Thus, semi-spherical beads were obtained in our study. Additionally, the
24 irregular head shape was observed with high distance (10 cm) and high CaCl₂ (15 g L⁻¹),
25 477 which correspond to the EE decrease (Table 1).
26
27
28
29
30
31
32
33
34
35
36

37 484 **4.3 Bioavailability and bioaccessibility of R-PE**

38
39

40 485 Figure 4 shows the bioaccessibility of encapsulated and non-encapsulated R-PE during
41 486 intestinal digestion. The encapsulation of R-PE significantly influenced the bioaccessibility
42 and bioavailability of pigment R-PE. The bioaccessibility of R-PE extract was significantly
43 487 higher than alginate/shellac microparticles, reaching values around 30.4 % at 180 min,
44 488 whereas the bioaccessibility from encapsulated R-PE was detected in the gastric and
45 489 intestinal phases, and reached values of 20.25 % at the end of the intestinal digestion
46 490 (180min).
47
48
49
50

51
52 492 The bioavailability of encapsulated and non-encapsulated R-PE at the end of intestinal
53 493 digestion is presented in Figure 5. Comparing R-PE samples, we observed that
54 494 encapsulated R-PE presented the highest percentages (6.0%) of bioavailability when
55 495 compared to non-encapsulated R-PE (2.41%) at 180min of intestinal digestion. At the
56 beginning of the intestinal absorption phase (permeate samples), it was noted that small
57 496 percentages of non-encapsulated and encapsulated R-PE from the initial total content were
58
59
60
61
62
63
64
65

498 available and passed through the membrane. We observed during each digestion time for
499 all samples was increased the R-PE content showed similar contents, but at the end of the
500 intestinal digestion, a significant difference was detected at 180min reached for non-
501 encapsulated and encapsulated R-PE 0.123 and 0.31 mg of R-PE g⁻¹ of biomass,
502 respectively.

503 **4.4 SDS-PAGE, phycoerythrin release, and NMR Spectra.**

504 Figure 6 outlines the SDS-PAGE profile of the different stages of the digestion samples,
505 where multiple protein bands ranging from 20 to 100 kDa can be observed, except for the
506 mouth and stomach. More intense bands eluted in the duodenum and intestine at around
507 50, 20-37kDa, suggesting that some bands correspond to Phycoerythrin. Thus, it is
508 possible to understand that the matrix core of the encapsulation of the phycoerythrin has
509 good resistance to mouth and stomach levels because no signal was reported. However,
510 signals between the concentrated and permeated phases in the intestine are similar in the
511 intense bands at different reaction times (30 and 180min). Finally, it is feasible to suggest
512 that phycoerythrin has a good controlled release in the function of matrix encapsulation
513 formulated at the intestinal level. These results have a good coincidence with the release
514 test evaluated in different pH (1-5), where the encapsulated R-PE at pH 1 does not exceed
515 10% of release content, while at pH 3 and 5 it remains, which may suggest a controlled
516 release after 180 min of exposure from the encapsulating matrix (Figure 7A).

517 Figure 7B presents the phycoerythrin release as a percentage of the total value with
518 respect to time, modeled using a second-order differential equation representing a two-
519 step first-order release response. The image shows that the release takes place at two
520 different stages, each describing a first-order response, resulting in an overall second-
521 order response. The first stage occurs from t=0, corresponding to pigment release from
522 the wall. The pigment concentration from the wall release then reaches a maximum value
523 at a specific moment, after which no further release occurs until the next stage begins.
524 Stage 2 shows a release restart, which releases the remaining pigment from the bead
525 core. From Table 3 a series of parameters related to the response were calculated from
526 the Laplace representation and shown in Table 4. The results suggest that the release can
527 be described by two stages: wall release (stage 1), with maximum values 273.2±35.5%
528 higher in stages 1 than those of pH 3 and 5, and core release, with maximum values
529 294.0±36.8% higher than the values obtained for pH 3 and 5. Core release (stage 2) for
530 pH =1 started 26.3±2.6 min after stage 2 started for pH 3, 5.

531 To carry out the ¹H NMR analyses, samples E1/FI and E1/IP were dissolved in DMSO-d₆.
532 The ¹H NMR spectra recorded for both samples are very similar (Figures 8, A, and B). In

533 both spectra, between 3.8 and 6.8 ppm, the singlets can clearly be seen due to the
534 hydroxyl group protons (OH) present in the oligosaccharide structure. In the interval 2.5
535 and 0.5 ppm, the signals associated with the aliphatic protons of methyl groups of amino
536 acids (alanine (Ala), leucine (Leu), isoleucine (Ile), and valine (Val)) are present in proteins
537 (Figure 8). Moreover, signals observed at 5.7, 6.7, 7.0, and 7.2 ppm can be assigned to
538 phycoerythrin double bonds (pyrrole skeleton). The presence of oligosaccharide hydroxyl
539 groups was confirmed by recording the ^1H NMR spectra in a mixture of deuterated DMSO
540 and D_2O as solvents. In this case, OH signals are not observed (Figure 8).

541 **4.5 Cell Viability of Lines HTC-116, G-361, U-937 and 1064SK**

542 The cytotoxicity of encapsulated and non-encapsulated R-PE (aqueous extract) was
543 determined in the human cancer cells (HCT-116; G-361; U-937) and healthy cells
544 (1064sk). After treating the cells with increasing concentrations of the two samples, cell
545 proliferation was evaluated using an MTT assay. As shown in Table 2, all the samples
546 exhibited relative inhibition ratios at all concentration levels and demonstrated a dose-
547 dependent inhibition in the growth of cancer cells. The lowest IC_{50} value in G-361 with
548 encapsulated R-PE was $4132 \pm 10.86 \mu\text{g mL}^{-1}$, in U-937 IC_{50} cells was $1251 \pm 4.83 \mu\text{g}$
549 mL^{-1} , in HCT-116 IC_{50} cells was $1076 \pm 8.46 \mu\text{g mL}^{-1}$ (Table 2). For R-PE aqueous extract
550 (non-encapsulated), the lowest IC_{50} value in HCT-116 cells IC_{50} was $144.5 \pm 3.96 \mu\text{g mL}^{-1}$,
551 while in U-937 IC_{50} was $2788 \pm 11.5 \mu\text{g mL}^{-1}$ and in G-361 was $2702 \pm 12.6 \mu\text{g mL}^{-1}$
552 (Table 2). On the other hand, in the healthy cells line in 1064sK, the encapsulated and
553 non-encapsulated R-PE were $3516 \pm 15.3 \mu\text{g mL}^{-1}$ and $4438 \pm 10.3 \text{mg mL}^{-1}$, respectively.
554 The highest SI values calculated for encapsulated R-PE also belonged to the three above-
555 mentioned cell lines, including HCT-116 (> 3.27), U-937 (> 0.86), and G-361 (> 0.26),
556 compared to the other cell lines (Table 2). The SI values calculated for the R-PE extract
557 for all the cell lines were high, ranging between 30.71 and 1.59, depending on the cell
558 line, indicating higher effectiveness of the R-PE extract on the cancer cell lines compared
559 to the encapsulated R-PE. These results have a cytotoxic effect on cancer and healthy
560 cells, where the R-PE aqueous extract presented relatively high antitumor activities against
561 HCT-116 cells.

562 563 **5.0 Discussion**

564 Algae, especially macroalgae, have recently emerged as a vast source of metabolites with
565 unique structures and nutritional and therapeutic activities, and this field is becoming one
566 of the hot challenges in food science and technology [23]. Our work is the first approach
567 in a new generation of potential ingredients based on alginate/shellac as biomaterials for

568 protecting R-PE to maintain biological activity and bioavailability under human
1 569 physiological conditions. To formulate the wall material, alginate/shellac has been
2 570 validated by other authors with good results in the efficiency of encapsulation for bioactive
3 571 like riboflavin [18], sunflower oil [20] and inclusive in a microorganism [19]. However, the
4 572 protection processes for phycobilin pigments have been little explored but have great
5 573 potential in the food industry, according to several studies [42–44]. In this sense, the R-
6 574 PE was successfully encapsulated by Taguchi optimization, which revealed that the high
7 575 efficiency is given with design point 1, reaching values close to 97.5 ± 0.71 % EE (Table
8 576 1). Similar results were obtained by Pan-tai et al. [45] for phycocyanin (C-PC), from the
9 577 microalga *Arthrospira platensis* (Cyanobacteria), under alginate formulation process to
10 578 beads by ionic gelation reached 98% EE. It was found that alginate and CaCl_2
11 579 concentration have a significant influence on the EE (%) and bead properties. In the same
12 580 line, Yan et al. [46] developed a wall material by an extrusion method using alginate and
13 581 chitosan as coating materials for the protection of the phycocyanin from *Arthrospira*
14 582 *platensis* (Cyanobacteria), which reached values around 56 % of EE. These values are
15 583 lower than our results, where the differences may be due to the combination of the
16 584 materials and the low concentration of CaCl_2 (2.5 %), in which the competition between
17 585 the two polymers to bind Ca^{2+} calcium ions affects the final composite gel structure. The
18 586 observations of Messaoud et al. [18] found that coating the capsules by Ca^{2+} reticulation
19 587 of shellac led to the formulation of a uniform and smooth layer that was closely related to
20 588 the amount of shellac and Ca^{2+} , were recommended concentration of CaCl_2 2 % (%W/V).
21 589 Also, Henning et al. [47] suggest that concentrations of CaCl_2 over 2 % (%W/V) are
22 590 enough to ensure the formation of cross-linked hydrogel alginate/shellac membranes.
23 591 However, there found a shrinking phenomenon of the alginate hydrogels during the coating
24 592 process. This shrinking might be induced by the depletion of cross-linked calcium ions in
25 593 the alginate hydrogel due to chemical reactions between the calcium ions and the shellac.
26 594 From our observations, we suggest that the range of CaCl_2 between 5 and 15 % (%W/V)
27 595 depends directly on the interaction with shellac, found high EE values (97.5%) at 5 %
28 596 (%W/V). Further studies are needed for another aspect that could describe the differences
29 597 in the thickness of the shellac layers being linked to the total amount of H^+ ions in the
30 598 capsules (adjusted by the pH value).

31 599 The SEM and fluorescence observation of alginate/shellac beads exhibited a semi-spherical
32 600 shape thanks to the intrinsic properties surface tension, density, and viscosity of the CaCl_2
33 601 solution before the encapsulation stage [20,48]. According to Chan [31], beads with SF
34 602 values lower than 0.05 are considered spherical beads. Therefore, the beads in our study
35 603 are semi-spherical. The irregular bead shape was observed with a high distance (10 cm)
36 604 and high CaCl_2 . However, the bead morphology became spherical as the distance of

605 extrusion and CaCl₂ on the %EE increased. According to Chan et al. [48], SF was an
606 efficient tool as a sphericity indicator to study the shape of the beads. Additionally,
607 spherical beads as an encapsulation system are more stable than irregular or non-spherical
608 shaped beads, as spherical beads have a low surface/volume ratio, producing a lower
609 diffusion of bioactive in the beads. Dried microcapsules presented diameters ranging from
610 0.8 to 1.20mm (Table 1). Despite the large size, these microcapsules may be used in solid
611 foods such as chocolate and cereal bars where the texture is not affected by the particle
612 size [19].

613 The alginate/shellac beads with the highest EE were subjected to the *in vitro* dynamic
614 digestion method (SIMUGIT). The percentage of R-PE found in the permeate stream was
615 lower than in the encapsulated R-PE, where we found 6.0 % of bioavailability at 180 min
616 of intestinal digestion. The R-PE bioavailability differed significantly depending on the wall
617 material; after the gastric step, the alginate/shellac beads contained 0.58mg g⁻¹ of R-PE,
618 a decrease of 89.6 % compared to the initial concentration (5.58 mg g⁻¹). In the same
619 vein, in the intestinal stage, the content available and passed through the microfiltration
620 membrane (0.05 µm) more R-PE was seen to be released, showing a decrease of 94.5 %
621 of R-PE compared to the initial concentration. Thus, the alginate/shellac as wall materials
622 for R-PE has an acceptable mechanism for protecting the pigment, which allows it to pass
623 through the mouth, stomach, and duodenum barriers and releasing the compound in a
624 controlled intestinal phase. According to Pimentel et al[23], enriching protein extracts from
625 *Porphyra dioica* (Nori) released at the intestinal level is advisable because it is in the
626 intestine where the proteins are degraded by enzymes and peptides are absorbed into the
627 bloodstream, thereby improving the antioxidant activity. Our DGGE analysis showed that
628 the fraction of the final digest was between 25-50KDa, where the profile of the extracted
629 protein is consistent with previous results reported by Pimentel et al[23] and Stack et al.
630 [49] for red algae. Similar conclusions were reported by Wu et al. [50], who evaluated the
631 *in vitro* digestion of R-PE and found that the final intestinal digestion still contained high
632 antioxidant activity in proteins fraction of <3 kDa. They indicate that digestion-resistant
633 antioxidant peptides of R-PE may be obtained by *in vitro* gastrointestinal proteinase
634 degradation. Likewise, Yabuta et al. [51] found that the R-PE from *Porphyra* sp extract is
635 readily digested to release the phycoerythrobilin compound during the gastrointestinal
636 digestion process of mammals. They also suggested that the various therapeutic activities
637 of phycoerythrin appear to be associated with the phycoerythrobilin compound released
638 during mammalian gastrointestinal digestion. On the other hand, Teixé-Roig et al. [52]
639 reported that the other phycobiliprotein C-phycoyanin (C-PC) was protected by double
640 emulsions containing pectin and sodium alginate presented high %EE and the most
641 suitable to prevent phycocyanin degradation during the digestion process. This suggests

642 that biological activity and safety can be enhanced after digestion. Also, Campos et al.
643 [53] reported that the same C-phycoyanin (C-PC) extract could be applied as a stable
644 blue dye in ice creams and highlight the increased antioxidant activity of the C-PC-added
645 products after *in vitro* simulated digestion.

646 A second-order model was proposed for describing the Phycoerythrin release into an
647 aqueous solution. The proposed model used differs from first-order models presented by
648 other researchers [18]. The second-order model described two stages, each described by
649 a first-order response and separated by a time delay. The first stage corresponded to wall
650 release diffusion, and the second to pigment release from the core. Regarding the
651 maximum release values, pH=1 showed a higher maximum $273.2 \pm 35.5 \%$ and $294.0 \pm$
652 36.8% in comparison to those of pH 3 and 5 for stages 1 and 2, respectively, with core
653 release (stage 2) starting 26.3 ± 2.6 min after stage 2 have started for pH 3, 5, showing
654 promising targeting properties with respect to time and pH. The results suggest that time
655 and pH modify the release of the pigment from the alginate matrix, showing potential for
656 targeting areas characterized by certain pH and retention time. Regarding using a unit
657 step signal as input to the second-order differential equation for describing the release of
658 pigment, this input signal selection could have been changed to a more straightforward
659 Dirac impulse function. This is because the integration of the Dirac impulse function can
660 be made equivalent to the unitary function. However, this would have required using a
661 third-order differential equation to describe the release, making the proposed model more
662 complex.

663 Unfortunately, the changes in R-PE concentration through digestion have low reports in
664 the literature. But it is clear that the biological activities of R-PE are maintained after the
665 *in vitro* digestion stage demonstrated by Yabuta et al. [51], Wu et al. [50], Stack et al.
666 [49], and Pimentel et al. [23]. Our research shows that the amount of encapsulated R-PE
667 released in the final stage of intestinal digestion (0.31 mg g^{-1}) is sufficient to cause a
668 cytotoxic reaction against human cancer cells. The IC_{50} values for HCT-116 (1076 ± 8.46)
669 and U-937 (1251 ± 4.83), as well as the SI values for the R-PE, encapsulated in these
670 cells (> 3.27 for HCT-116 and > 0.86 for U-937) suggest encapsulated as a promising
671 therapeutic candidate, particularly on gastro and blood cancers. Knowing that the greater
672 the SI value is, the more selective it is, and SI values over 3 indicate general toxicity [41],
673 we concluded that compared to encapsulated R-PE, (SI: 30.71), R-PE extracts non-
674 encapsulated are better candidates for growth suppression of all the examined cell lines
675 with SI values > 3 . These observations can be attributed to the wall materials
676 (alginate/shellac) possibly affecting the growth factors of human cells, primarily due to
677 alginate, which has been shown to have catalytic characteristics in human cells [54]. Future

678 studies in an *in vivo* system are needed to relate antiproliferative and antioxidant activities
679 as potential nutraceuticals.

680

681 **6.0 Conclusions**

682 This study provided insights into the process conditions to prepare beads with a high EE
683 of R-PE and the evolution under *in vitro* gastrointestinal digestion microcapsules. The
684 variables process for R-PE encapsulation was obtained using a feeding flow of 20mL h⁻¹, 5
685 cm of distance, and 5 gr L⁻¹ of CaCl₂. The encapsulation under optimal conditions showed
686 97.5% showing a good coincidence with the predictive OTE values (97 %). The beads
687 presented a semi-spherical shape and were free of pores with a size of 1.2 mm. The *in*
688 *vitro* digestion showed that the alginate/shellac beads were 2.5 times higher in
689 bioavailability than non-encapsulated R-PE extract at intestine stage digestion with a
690 concentration of 0.31 mg of R-PE. Finally, the R-PE charged in the encapsulate can be
691 used as a potential delivery system for aqueous extract and give a therapeutic response
692 according to the IC₅₀ (144 µg mL⁻¹) values found for the R-PE for colon cancer. We suggest
693 that the encapsulation system of R-PE can be incorporated into a food matrix for
694 nutraceutical applications.

695

696 **Credit authorship contribution statement**

697 Conceptualization, P.C-V., M.R., F.L.F. and R.A-D.; methodology C.A. and P.C-V.;
698 mathematical model methodology, C.A; SIMUGIT methodology, A.M-F.; SIMUGIT
699 supervision and writing A.M-F.; NMR methodology, D.F-R and J.M.L.; NMR experiment
700 supervision and writing, J.M.L; data curation, C.A and P.C-V; validation, P.C-V; writing
701 original draft preparation, P.C-V.; writing-review and editing, P.C-V., M.R., F.L.F. J.M.L.,
702 A.M-F., and R.A-D.; visualization, P.C-V; supervision, M.R., F.L.F. and R.A-D. All authors
703 have read and agreed to the published version of the manuscript.

704 **Declaration of competing interest**

705 The authors declare that there are no conflicts of interest.

706 **Data availability**

707 The data that support the findings of this study are openly available from the
708 corresponding author [P.C-V.] on request if the editor or reviewer needs it.

709 **Acknowledgments**

1
2
3 710 We gratefully acknowledge the Department of Chemical Engineering of the University of
4 711 Granada and the IBYDA Center of the University of Malaga for resource and technical
5 712 support. P.C.V. thanks the Asociación Iberoamericana de Postgrado (AUIP) and the
6 713 University of Malaga for PhD scholarship research. We also want to thank Mr. Jaime
7 714 Zamorano from GELYMAR Company (Chile) and NOREVO Company (Germany) for
8
9 715 collaborating on this research project.

10
11
12
13 716 **Funding information**

14
15
16 717 This study was supported by the Project "Blue nutricosmeceuticals with cyanobacteria and
17 718 macroalgae (NAZCA)-Nutricosmeceutica azul con cianobacterias y algas (NAZCA-) PY20-
18
19 719 00458 by the Andalusian Government, Spain.

20
21
22 720

23
24 721

25
26
27 722

28
29
30 723

31
32 724

33
34
35 725

36
37
38 726

39
40
41 727

42
43 728

44
45
46 729

47
48
49 730

50
51 731

52
53
54 732

55
56 733

57
58
59 734

60
61
62
63
64
65

735 **References**

- 1
2
3 736 [1] E. Assadpour, S.M. Jafari, Importance of release and bioavailability studies for
4 737 nanoencapsulated food ingredients, *Release and Bioavailability of Nanoencapsulated Food*
5 738 *Ingredients*. (2020) 1–24. <https://doi.org/10.1016/B978-0-12-815665-0.00001-1>.
6
7 739 [2] H. Rostamabadi, E. Assadpour, H.S. Tabarestani, S.R. Falsafi, S.M. Jafari, Electrospinning
8 740 approach for nanoencapsulation of bioactive compounds; recent advances and innovations,
9 741 *Trends Food Sci Technol*. 100 (2020) 190–209. <https://doi.org/10.1016/J.TIFS.2020.04.012>.
11 742 [3] S.R. Falsafi, S.P. Bangar, V. Chaudhary, E. Hosseini, Z. Mokhtari, A.C. Karaca, M.K. Samota, D.
12 743 Goswami, V. Krishnan, G. Askari, H. Rostamabadi, Recent advances in oral delivery of bioactive
13 744 molecules: Focus on prebiotic carbohydrates as vehicle matrices, *Carbohydr Polym*. 298 (2022)
14 745 120074. <https://doi.org/10.1016/J.CARBPOL.2022.120074>.
16 746 [4] I.J. Joye, D.J. McClements, Biopolymer-based nanoparticles and microparticles: Fabrication,
17 747 characterization, and application, *Curr Opin Colloid Interface Sci*. 19 (2014) 417–427.
18 748 <https://doi.org/10.1016/J.COCIS.2014.07.002>.
20 749 [5] A. Araiza-Calahorra, A. Sarkar, Pickering emulsion stabilized by protein nanogel particles for
21 750 delivery of curcumin: Effects of pH and ionic strength on curcumin retention, *Food Structure*.
22 751 21 (2019) 100113. <https://doi.org/10.1016/J.FOOSTR.2019.100113>.
24 752 [6] R.S. Hosseini, A. Rajaei, Potential Pickering emulsion stabilized with chitosan-stearic acid
25 753 nanogels incorporating clove essential oil to produce fish-oil-enriched mayonnaise, *Carbohydr*
26 754 *Polym*. 241 (2020) 116340. <https://doi.org/10.1016/J.CARBPOL.2020.116340>.
28 755 [7] T.K. Nguyen, H. Negishi, S. Abe, T. Ueno, Construction of supramolecular nanotubes from
29 756 protein crystals, *Chem Sci*. 10 (2019) 1046–1051. <https://doi.org/10.1039/C8SC04167A>.
31 757 [8] N. Devi, M. Sarmah, B. Khatun, T.K. Maji, Encapsulation of active ingredients in polysaccharide–
32 758 protein complex coacervates, *Adv Colloid Interface Sci*. 239 (2017) 136–145.
33 759 <https://doi.org/10.1016/J.CIS.2016.05.009>.
35 760 [9] A. Madene, M. Jacquot, J. Scher, S. Desobry, Flavour encapsulation and controlled release – a
36 761 review, *Int J Food Sci Technol*. 41 (2006) 1–21. <https://doi.org/10.1111/J.1365-2621.2005.00980.X>.
38 762
39 763 [10] S.H. Hu, C.H. Tsai, C.F. Liao, D.M. Liu, S.Y. Chen, Controlled rupture of magnetic polyelectrolyte
40 764 microcapsules for drug delivery, *Langmuir*. 24 (2008) 11811–11818.
41 765 https://doi.org/10.1021/LA801138E/SUPPL_FILE/LA801138E_SI_001.PDF.
43 766 [11] S.N. Pawar, K.J. Edgar, Alginate derivatization: a review of chemistry, properties and
44 767 applications, *Biomaterials*. 33 (2012) 3279–3305.
45 768 <https://doi.org/10.1016/J.BIOMATERIALS.2012.01.007>.
47 769 [12] M. Mancini, M. Moresi, R. Rancini, Uniaxial compression and stress relaxation tests on alginate
48 770 gels, *J Texture Stud*. 30 (1999) 639–657. <https://doi.org/10.1111/J.1745-4603.1999.TB00235.X>.
50 771
51 772 [13] J. Burgain, C. Gaiani, M. Linder, J. Scher, Encapsulation of probiotic living cells: From laboratory
52 773 scale to industrial applications, *J Food Eng*. 104 (2011) 467–483.
53 774 <https://doi.org/10.1016/J.JFOODENG.2010.12.031>.
54
55
56
57
58
59
60
61
62
63
64
65

- 775 [14] S.C. Chew, K.L. Nyam, Microencapsulation of kenaf seed oil by co-extrusion technology, *J Food*
1 776 *Eng.* 175 (2016) 43–50. <https://doi.org/10.1016/J.JFOODENG.2015.12.002>.
- 2
3 777 [15] D. Schell, C. Beermann, Fluidized bed microencapsulation of *Lactobacillus reuteri* with sweet
4 778 whey and shellac for improved acid resistance and in-vitro gastro-intestinal survival, *Food*
5 779 *Research International.* 62 (2014) 308–314. <https://doi.org/10.1016/J.FOODRES.2014.03.016>.
- 6
7 780 [16] A.R. Patel, D. Schatteman, W.H. De Vos, K. Dewettinck, Shellac as a natural material to structure
8 781 a liquid oil-based thermo reversible soft matter system, *RSC Adv.* 3 (2013) 5324–5327.
9 782 <https://doi.org/10.1039/C3RA40934A>.
- 10
11 783 [17] A. Samir, F.H. Ashour, A.A.A. Hakim, M. Bassyouni, Recent advances in biodegradable polymers
12 784 for sustainable applications, *Npj Materials Degradation* 2022 6:1. 6 (2022) 1–28.
13 785 <https://doi.org/10.1038/s41529-022-00277-7>.
- 14
15 786 [18] G. Ben Messaoud, L. Sánchez-González, L. Probst, C. Jeandel, E. Arab-Tehrany, S. Desobry,
16 787 Physico-chemical properties of alginate/shellac aqueous-core capsules: Influence of
17 788 membrane architecture on riboflavin release, *Carbohydr Polym.* 144 (2016) 428–437.
18 789 <https://doi.org/10.1016/J.CARBPOL.2016.02.081>.
- 19
20 790 [19] M.P. Silva, F.L. Tulini, M.M. Ribas, M. Penning, C.S. Fávaro-Trindade, D. Poncelet, Microcapsules
21 791 loaded with the probiotic *Lactobacillus paracasei* BGP-1 produced by co-extrusion technology
22 792 using alginate/shellac as wall material: Characterization and evaluation of drying processes,
23 793 *Food Res Int.* 89 (2016) 582–590. <https://doi.org/10.1016/J.FOODRES.2016.09.008>.
- 24
25 794 [20] E. Morales, M. Rubilar, C. Burgos-Díaz, F. Acevedo, M. Penning, C. Shene, Alginate/Shellac
26 795 beads developed by external gelation as a highly efficient model system for oil encapsulation
27 796 with intestinal delivery, *Food Hydrocoll.* 70 (2017) 321–328.
28 797 <https://doi.org/10.1016/j.foodhyd.2017.04.012>.
- 29
30 798 [21] M. Minekus, M. Alminger, P. Alvito, S. Ballance, T. Bohn, C. Bourlieu, F. Carrière, R. Boutrou, M.
31 799 Corredig, D. Dupont, C. Dufour, L. Egger, M. Golding, S. Karakaya, B. Kirkhus, S. Le Feunteun, U.
32 800 Lesmes, A. Maclerzanka, A. MacKie, S. Marze, D.J. McClements, O. Ménard, I. Recio, C.N.
33 801 Santos, R.P. Singh, G.E. Vegarud, M.S.J. Wickham, W. Weitschies, A. Brodkorb, A standardised
34 802 static in vitro digestion method suitable for food – an international consensus, *Food Funct.* 5
35 803 (2014) 1113–1124. <https://doi.org/10.1039/C3FO60702J>.
- 36
37 804 [22] Q. Xu, H. Hong, J. Wu, X. Yan, Bioavailability of bioactive peptides derived from food proteins
38 805 across the intestinal epithelial membrane: A review, *Trends Food Sci Technol.* 86 (2019) 399–
39 806 411. <https://doi.org/10.1016/J.TIFS.2019.02.050>.
- 40
41 807 [23] F.B. Pimentel, M. Cermeño, T. Kleekayai, P.A. Harnedy, R.J. FitzGerald, R.C. Alves, M.B.P.P.
42 808 Oliveira, Effect of in vitro simulated gastrointestinal digestion on the antioxidant activity of the
43 809 red seaweed *Porphyra dioica*, *Food Research International.* 136 (2020) 109309.
44 810 <https://doi.org/10.1016/J.FOODRES.2020.109309>.
- 45
46 811 [24] W. Li, H.-N. Su, Y. Pu, J. Chen, L.-N. Liu, Q. Liu, S. Qin, Phycobiliproteins: Molecular structure,
47 812 production, applications, and prospects, *Biotechnol Adv.* 37 (2019) 340–353.
48 813 <https://doi.org/https://doi.org/10.1016/j.biotechadv.2019.01.008>.
- 49
50 814 [25] R. Thangam, S. Sundarraj, R. Vivek, V. Suresh, S. Sivasubramanian, M. Paulpandi, S.V. Karthick,
51 815 A.S. Ragavi, S. Kannan, Theranostic potentials of multifunctional chitosan-silver-phycoerythrin
- 52
53
54
55
56
57
58
59
60
61
62
63
64
65

- 816 nanocomposites against triple negative breast cancer cells, RSC Adv. 5 (2015).
1 817 <https://doi.org/10.1039/c4ra14043e>.
- 2
3 818 [26] N. Senthilkumar, R. Thangam, P. Murugan, V. Suresh, C. Kurinjimalar, G. Kavitha, S.
4 819 Sivasubramanian, R. Rengasamy, Hepato-protective effects of R-phycoerythrin-rich protein
5 820 extract of *Portieria hornemannii* (Lyngbye) Silva against DEN-induced hepatocellular
6 821 carcinoma, J Food Biochem. 42 (2018) 1–11. <https://doi.org/10.1111/jfbc.12695>.
- 7
8
9 822 [27] S. Ulagesan, T.J. Nam, Y.H. Choi, Extraction and Purification of R-Phycoerythrin Alpha Subunit
10 823 from the Marine Red Algae *Pyropia Yezoensis* and Its Biological Activities, Molecules 2021, Vol.
11 824 26, Page 6479. 26 (2021) 6479. <https://doi.org/10.3390/MOLECULES26216479>.
- 12
13 825 [28] P. Castro-Varela, P.S.M. Celis-Pla, F.L. Figueroa, M. Rubilar, Highly Efficient Water-Based
14 826 Extraction of Biliprotein R-Phycoerythrin From Marine the Red-Macroalga *Sarcopeltis*
15 827 *skottsbergii* by Ultrasound and High-Pressure Homogenization Methods, Front Mar Sci. 0
16 828 (2022) 988. <https://doi.org/10.3389/FMARS.2022.877177>.
- 17
18
19 829 [29] A. Bennett, L. Bogobad, Complementary chromatic adaptation in a filamentous blue-green
20 830 alga, Journal of Cell Biology. 58 (1973) 419–435. <https://doi.org/10.1083/jcb.58.2.419>.
- 21
22 831 [30] X. Ge, Z. Wan, N. Song, A. Fan, R. Wu, Efficient methods for the extraction and
23 832 microencapsulation of red pigments from a hybrid rose, J Food Eng. 94 (2009) 122–128.
24 833 <https://doi.org/10.1016/J.JFOODENG.2009.02.021>.
- 25
26
27 834 [31] E.S. Chan, Preparation of Ca-alginate beads containing high oil content: Influence of process
28 835 variables on encapsulation efficiency and bead properties, Carbohydr Polym. 84 (2011) 1267–
29 836 1275. <https://doi.org/10.1016/J.CARBPOL.2011.01.015>.
- 30
31
32 837 [32] C. Alarcon, C. Shene, Arduino Soft Sensor for Monitoring *Schizochytrium* sp. Fermentation, a
33 838 Proof of Concept for the Industrial Application of Genome-Scale Metabolic Models in the
34 839 Context of Pharma 4.0, Processes. 10 (2022) 2226. <https://doi.org/10.3390/pr10112226>.
- 35
36 840 [33] E. Rivas-Montoya, J. Miguel Ochando-Pulido, J. Manuel López-Romero, A. Martinez-Ferez,
37 841 Application of a novel gastrointestinal tract simulator system based on a membrane bioreactor
38 842 (SimuGIT) to study the stomach tolerance and effective delivery enhancement of
39 843 nanoencapsulated macelignan, Chem Eng Sci. 140 (2016) 104–113.
40 844 <https://doi.org/10.1016/J.CES.2015.10.006>.
- 41
42
43 845 [34] A. Brodkorb, L. Egger, M. Alminger, P. Alvito, R. Assunção, S. Ballance, T. Bohn, C. Bourlieu-
44 846 Lacanal, R. Boutrou, F. Carrière, A. Clemente, M. Corredig, D. Dupont, C. Dufour, C. Edwards,
45 847 M. Golding, S. Karakaya, B. Kirkhus, S. Le Feunteun, U. Lesmes, A. Macierzanka, A.R. Mackie, C.
46 848 Martins, S. Marze, D.J. McClements, O. Ménard, M. Minekus, R. Portmann, C.N. Santos, I.
47 849 Souchon, R.P. Singh, G.E. Vegarud, M.S.J. Wickham, W. Weitschies, I. Recio, INFOGEST static in
48 850 vitro simulation of gastrointestinal food digestion, Nat Protoc. 14 (2019) 991–1014.
49 851 <https://doi.org/10.1038/s41596-018-0119-1>.
- 50
51
52
53 852 [35] P. Abad, N. Arroyo-Manzanares, E. Rivas-Montoya, J.M. Ochando-Pulido, E. Guillamon, A.M.
54 853 García-Campaña, A. Martinez-Ferez, Effects of different vehiculization strategies for the allium
55 854 derivative propyl propane thiosulfonate during dynamic simulation of the pig gastrointestinal
56 855 tract, Can J Anim Sci. 99 (2019) 244–253. [https://doi.org/10.1139/CJAS-2018-0063-](https://doi.org/10.1139/CJAS-2018-0063/SUPPL_FILE/CJAS-2018-0063SUPPLA.DOCX)
57 856 0063/SUPPL_FILE/CJAS-2018-0063SUPPLA.DOCX.
- 58
59
60
61
62
63
64
65

- 857 [36] E. González, A.M. Gómez-Caravaca, B. Giménez, R. Cebrián, M. Maqueda, A. Martínez-Férez,
1 858 A. Segura-Carretero, P. Robert, Evolution of the phenolic compounds profile of olive leaf
2 859 extract encapsulated by spray-drying during in vitro gastrointestinal digestion, *Food Chem.* 279
3 860 (2019) 40–48. <https://doi.org/10.1016/J.FOODCHEM.2018.11.127>.
- 4 861 [37] M.T. Ariza, P. Reboredo-Rodríguez, L. Cervantes, C. Soria, E. Martínez-Ferri, C. González-
5 862 Barreiro, B. Cancho-Grande, M. Battino, J. Simal-Gándara, Bioaccessibility and potential
6 863 bioavailability of phenolic compounds from achenes as a new target for strawberry breeding
7 864 programs, *Food Chem.* 248 (2018) 155–165.
8 865 <https://doi.org/10.1016/J.FOODCHEM.2017.11.105>.
- 9 866 [38] W. Wang, R. Vignani, M. Scali, M. Cresti, A universal and rapid protocol for protein extraction
10 867 from recalcitrant plant tissues for proteomic analysis, *Electrophoresis.* 27 (2006) 2782–2786.
11 868 <https://doi.org/10.1002/ELPS.200500722>.
- 12 869 [39] U.K. Laemmli, Cleavage of Structural Proteins during the Assembly of the Head of
13 870 Bacteriophage T4, *Nature* 1970 227:5259. 227 (1970) 680–685.
14 871 <https://doi.org/10.1038/227680a0>.
- 15 872 [40] R.T. Abdala Díaz, V. Casas Arrojo, M.A. Arrojo Agudo, C. Cárdenas, S. Dobretsov, F.L. Figueroa,
16 873 Immunomodulatory and Antioxidant Activities of Sulfated Polysaccharides from *Laminaria*
17 874 *ochroleuca*, *Porphyra umbilicalis*, and *Gelidium corneum*, *Marine Biotechnology.* 21 (2019).
18 875 <https://doi.org/10.1007/s10126-019-09905-x>.
- 19 876 [41] G. Indrayanto, G.S. Putra, F. Suhud, Validation of in-vitro bioassay methods: Application in
20 877 herbal drug research, *Profiles Drug Subst Excip Relat Methodol.* 46 (2021) 273–307.
21 878 <https://doi.org/10.1016/BS.PODRM.2020.07.005>.
- 22 879 [42] C. Juin, J.R. Chérourvier, V. Thiéry, A.L. Gagez, J.B. Bérard, N. Joguet, R. Kaas, J.P. Cadoret, L.
23 880 Picot, Microwave-assisted extraction of phycobiliproteins from *Porphyridium purpureum*, *Appl*
24 881 *Biochem Biotechnol.* 175 (2015). <https://doi.org/10.1007/s12010-014-1250-2>.
- 25 882 [43] M. Jacotet-Navarro, N. Rombaut, S. Deslis, A.S. Fabiano-Tixier, F.X. Pierre, A. Bily, F. Chemat,
26 883 Towards a “dry” bio-refinery without solvents or added water using microwaves and
27 884 ultrasound for total valorization of fruit and vegetable by-products, *Green Chemistry.* 18
28 885 (2016). <https://doi.org/10.1039/c5gc02542g>.
- 29 886 [44] T. Pereira, S. Barroso, S. Mendes, R.A. Amaral, J.R. Dias, T. Baptista, J.A. Saraiva, N.M. Alves,
30 887 M.M. Gil, Optimization of phycobiliprotein pigments extraction from red algae *Gracilaria*
31 888 *gracilis* for substitution of synthetic food colorants, *Food Chem.* 321 (2020) 126688.
32 889 <https://doi.org/10.1016/j.foodchem.2020.126688>.
- 33 890 [45] W. Pan-utai, S. Iamtham, Journal of King Saud University – Science Physical extraction and
34 891 extrusion entrapment of C-phycoyanin from *Arthrospira platensis*, *J King Saud Univ Sci.* (2018).
35 892 <https://doi.org/10.1016/j.jksus.2018.05.026>.
- 36 893 [46] M. Yan, B. Liu, X. Jiao, S. Qin, Preparation of phycocyanin microcapsules and its properties,
37 894 *Food and Bioproducts Processing.* 92 (2014) 89–97.
38 895 <https://doi.org/10.1016/J.FBP.2013.07.008>.
- 39 896 [47] S. Henning, S. Leick, M. Kott, H. Rehage, D. Suter, Sealing liquid-filled pectinate capsules with a
40 897 shellac coating, *J Microencapsul.* 29 (2012) 147–155.
41 898 <https://doi.org/10.3109/02652048.2011.635220>.
- 42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

899 [48] E.S. Chan, B.B. Lee, P. Ravindra, D. Poncelet, Prediction models for shape and size of ca-alginate
1 900 macrobeads produced through extrusion–dripping method, *J Colloid Interface Sci.* 338 (2009)
2 901 63–72. <https://doi.org/10.1016/J.JCIS.2009.05.027>.

4 902 [49] J. Stack, P.R. Tobin, A. Gietl, P.A. Harnedy, D.B. Stengel, R.J. FitzGerald, Seasonal variation in
5 903 nitrogenous components and bioactivity of protein hydrolysates from *Porphyra dioica*, *Journal*
6 904 *of Applied Phycology* 2017 29:5. 29 (2017) 2439–2450. [https://doi.org/10.1007/S10811-017-](https://doi.org/10.1007/S10811-017-1063-0)
7 905 1063-0.

10 906 [50] Q. Wu, X.P. Fu, L.C. Sun, Q. Zhang, G.M. Liu, M.J. Cao, Q.F. Cai, Effects of physicochemical
11 907 factors and in vitro gastrointestinal digestion on antioxidant activity of R-phycoerythrin from
12 908 red algae *Bangia fusco-purpurea*, *Int J Food Sci Technol.* 50 (2015) 1445–1451.
13 909 <https://doi.org/10.1111/IJFS.12775>.

16 910 [51] Y. Yabuta, H. Fujimura, C.S. Kwak, T. Enomoto, F. Watanabe, Antioxidant Activity of the
17 911 Phycoerythrobilin Compound Formed from a Dried Korean Purple Laver (*Porphyra* sp.) during
18 912 in Vitro Digestion, *Food Sci Technol Res.* 16 (2010) 347–352.
19 913 <https://doi.org/10.3136/FSTR.16.347>.

22 914 [52] J. Teixé-Roig, G. Oms-Oliu, S. Ballesté-Muñoz, I. Odriozola-Serrano, O. Martín-Belloso,
23 915 Encapsulation and controlled release of phycocyanin during the in vitro digestion using
24 916 polysaccharide-added double emulsions (W1/O/W2), *Food Structure.* 31 (2022) 100249.
25 917 <https://doi.org/10.1016/J.FOOSTR.2021.100249>.

27 918 [53] M. Campos Assumpção de Amarante, A.R. Cavalcante Braga, L. Sala, S. Juliano Kalil, Colour
28 919 stability and antioxidant activity of C-phycocyanin-added ice creams after in vitro digestion,
29 920 *Food Research International.* 137 (2020) 109602.
30 921 <https://doi.org/10.1016/J.FOODRES.2020.109602>.

33 922 [54] K.Y. Lee, D.J. Mooney, Alginate: properties and biomedical applications, *Prog Polym Sci.* 37
34 923 (2012) 106. <https://doi.org/10.1016/J.PROGPOLYMSCI.2011.06.003>.

36 924
37
38
39 925
40
41 926
42
43 927
44
45 928
46
47 929
48
49 930
50
51 931
52
53 932
54
55
56
57
58
59
60
61
62
63
64
65

933

1

934

2

935

3

936

4

937

5

938

6

939

7

940

8

941

9

942

10

943

11

944

12

945

13

946

14

947

15

948

16

949

17

950

18

951

19

952

20

953

21

954

22

955

23

956

24

957

25

958

26

959

27

960

28

961

29

962




Figure 1. Effect of the working levels of each variable on the encapsulation efficiency.




Figure 2. Confocal microscopic for 1) design point N°1 (97.5%EE) and 2) presence of R-phycoerythrin by fluorescence.




Figure 3. Morphology of the beads by scanning microscopy (SEM) for a) design point N°1, b) design point N°4, and c) magnification of 500X for the surface of the beads of design point N°4.




Figure 4. Bioaccessibility (%) of R-PE extract and encapsulated R-PE during *in vitro* gastrointestinal digestion. Bars with an asterisk indicate a significant difference ($p < 0.05$) between encapsulated R-PE and R-PE extract.




Figure 5. Bioavailability (%) of R-PE extract and encapsulated R-PE during *in vitro* gastrointestinal digestion. A line with an asterisk indicates a significant difference ($p < 0.05$) between encapsulated R-PE and R-PE extract.

1010
1
2
3 1011
4
5
6 1012
7
8
9
10 1013
11
12
13 1014
14
15
16 1015
17
18
19 1016
20
21
22 1017
23
24
25
26 1018
27
28
29 1019
30
31
32 1020
33
34 1021
35
36 1022
37
38 1023
39 1024
40
41 1025
42
43 1026
44 1027
45
46 1028
47 1029
48
49 1030
50
51 1031
52
53 1032
54
55 1033
56
57 1034
58 1035
59
60 1036
61
62
63
64
65






Figure 6. Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) profile of encapsulated R-PE from a different stage of *in vitro* simulated digestion (simuGIT). 50µg of protein were loaded into the corresponding lane. MW: Molecular weight marker; D: Duoden; RS30': Retentate streams at 30min; RS180': Retentate streams at 180min; PS30': Permeate streams at 30min; PS180': Permeate streams at 180min; M: Mouth; S: Stomach.



A



B

Figure 7. Phycoerythrin release as a percentage of total with respect to time, A) Experimental R-PE release from alginate/shellac capsules during 250min at different pH values. Points with asterisks indicate significant differences ($p < 0.05$). B) modeled using a second-order differential equation representing a two-step first-order release response.

1038
1039
1040
1041
1042
1043
1044
1045
1046
1047

Table 1. Encapsulation efficiency of R-PE, sphericity factor, and particle size using the orthogonal matrix L₄ (2³).

Design point	Orthogonal Matrix L ₄ (2 ³)			Characterization of beads		Encapsulation efficiency
	Flow (mL h ⁻¹)	Distance (cm)	CaCl ₂ (gr L ⁻¹)	Sphericity factor (SF)	Size (mm)	%EE
1	20 (L ₁)	5 (L ₁)	5 (L ₁)	0.06 ± 0.02	1.2 ± 0.2	97.5 ± 0.7
2	20 (L ₁)	10 (L ₂)	15 (L ₂)	0.10 ± 0.03	1.6 ± 0.1	89 ± 1.41
3	90 (L ₂)	5 (L ₁)	15 (L ₂)	0.09 ± 0.05	1.1 ± 0.2	90 ± 1.41
4	90 (L ₂)	10 (L ₂)	5 (L ₁)	0.07 ± 0.01	1.1 ± 0.1	95.5 ± 0.71

Table 2. Cytotoxicity index (IC₅₀) and selective index (SI) for encapsulated and non-encapsulated R-PE on the different cell lines: 1064 sK (human gingival fibroblast cell line), HCT-116 (human colon cancer), G-361 (human melanoma), U-937 (human leukemia).

Samples	Health and Antiproliferative active cell lines	Cytotoxicity Index IC ₅₀ (µg mL ⁻¹).	Selectivity Index (SI)
Encapsulated	1064sK	3516 ±15.3	-
	HCT-116	1076 ± 8.46	3.27
	U-937	1251 ± 4.83	0.86
	G-361	4132 ± 10.86	0.26
Non-Encapsulated (R-PE extract)	1064sK	4438 ± 10.3	-
	HCT-116	144.5 ± 3.96	30.71
	U-937	2702 ±12.6	1.59
	G-361	2788 ±11.5	1.64

Table 3: Parameters for the second order model for Phycoerythrin release.

	a_1	a_2	c_1	c_2	t_d	NRMSE
pH=1	0.125	0.995	0.075	0.243	101.573	15.944
pH=3	0.038	0.297	0.092	0.258	73.452	28.948
pH=5	0.130	0.239	0.273	0.266	77.107	24.870

Table 4: Response of release of pigment.

	max release stage 1	max value stage 2	Stabilization time stage 1 (min)	Stabilization time stage 2 (min)	Time delay
pH=1	1.657	5.758	66.490	20.617	101.573
pH=3	0.416	1.565	54.571	19.357	73.452
pH=5	0.476	1.371	18.315	18.765	77.107

CONFLICT OF INTEREST

The authors declare that there are no conflicts of interest.

BIOETHICAL APPROVALS

Experiments were conducted under notifications A/ES/12/I-22 and A/ES/12/24 to Ministry of Ecological Transition and Demographic Challenge and approval 100-2018-T of the UMA Bioethics commission.

CRedit author statement

Conceptualization, P.C-V., M.R., F.L.F. and R.A-D.; methodology C.A. and P.C-V.; mathematical model methodology and Taguchi optimization, C.A; SIMUGIT methodology, A.M-F.; SIMUGIT supervision and writing A.M-F.; NMR methodology, D.F-R and J.M.L.; NMR experiment supervision and writing, J.M.L; data curation, C.A and P.C-V; validation, P.C-V; writing original draft preparation, P.C-V.; writing-review and editing, P.C-V., M.R., F.L.F. J.M.L., A.M-F., and R.A-D.; visualization, P.C-V; supervision, M.R., F.L.F. and R.A-D. All authors have read and agreed to the published version of the manuscript.